Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry

Leonardo De Luca1*, MD, PhD, FACC, FESC; Fabrizio D’Ascenzo2, MD; Giuseppe Musumeci3, MD; Francesco Saia4, MD; Guido Parodi5, MD; Ferdinando Varbella6, MD; Alfredo Marchese7, MD; Stefano De Servi8, MD, FESC; Sergio Berti9, MD; Leonardo Bolognese10, MD, FESC; on behalf of the SCOPE Investigators